-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...
-
Product Insights
NewSimplexvirus (HSV) Infections – Drugs In Development, 2024
Empower your strategies with our Simplexvirus (HSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Herpes simplex virus (HSV) infections, also known as simplexvirus infections, are caused by two types of viruses: HSV-1 and HSV-2. HSV-1 typically causes oral herpes, manifesting as cold sores around the mouth, while HSV-2 is primarily responsible for genital herpes. However, both types can cause infections in either location. These infections are highly contagious and transmitted through direct contact with an...
-
Product Insights
NewSeasonal Influenza – Drugs In Development, 2024
Empower your strategies with our Seasonal Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal influenza, commonly referred to as "the flu", is a contagious respiratory illness caused by influenza viruses. It typically occurs in outbreaks during the fall and winter months, peaking between December and February in the Northern Hemisphere. The flu can cause mild to severe illness and, in some cases, can lead to hospitalization or even death, especially among vulnerable populations. Symptoms of...
-
Product Insights
NewChikungunya Fever – Drugs In Development, 2024
Empower your strategies with our Chikungunya Fever – Drugs In Development, 2024 report and make more profitable business decisions. Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting, and rash and fever. Treatment includes use of non-steroidal...
-
Product Insights
NewAvian Influenza – Drugs In Development, 2024
Empower your strategies with our Avian Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Avian influenza, commonly referred to as bird flu, is a viral infection that primarily affects birds, especially poultry such as chickens and turkeys. Various strains of avian influenza viruses exist, some of which can cause severe illness in birds and, in certain cases, pose a risk to human health. Avian influenza viruses belong to the influenza A virus family and are classified...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 0.75 Percent Nyxol Eye Drop in Mydriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 0.75 Percent Nyxol Eye Drop in Mydriasis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.0.75 Percent Nyxol Eye Drop in MydriasisDrug Details: Phentolamine mesylate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Norovirus [Strains Norwalk Gi.1 + Sydney Gii.4] (Bivalent) Vaccine in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Norovirus [Strains Norwalk Gi.1 +...